Clinical trials: DLBCL, open to volunteers
CNS Lymphoma
Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients
This study is designed as an open-label, prospective, single-arm, single-center trial aimed at evaluating the efficacy and safety of MTX or Thiotepa combined with Orelabrutinib and standard chemotherapy regimens in the treatment…
- Trial name
- NCT06901999
- Testing
- Orelabrutinib, RCHOP+MTX or Thiotepa
- Volunteers
- 23 people
- Sponsor
- Ruijin Hospital
Pirtobrutinib, Immunochemotherapy
Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement
This is an open-label, prospective, single-arm, multicenter study designed to evaluate the efficacy and safety of MTX plus pirtobrutinib combined with routinely-used clinical chemoimmunotherapy regimens in patients with DLBCL and…
- Conditions
- Pirtobrutinib, Immunochemotherapy, DLBCL - Diffuse Large B Cell Lymphoma, CNS Involvement of Systemic Lymphoma
- Trial name
- NCT07812493
- Testing
- pirtobrutinib+MTX+immunolchemotherapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Pengpeng Xu
B Cell Malignancies
A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies
This is a phase I/II trial of T-cell expressing an anti-CD22 Chimeric-Antigen-Receptor (CAR) in patients with CD22 expressing B-cell malignancies.
- Trial name
- NCT07135466
- Testing
- CD22 CAR-T cells
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Sheba Medical Center
B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Long-term Follow up Local Registry Study of Kymriah in South Korea
This study is multicenter, primary data collection, non-interventional registry study to assess long-term safety, secondary malignancy risk, and effectiveness of tisagenlecleucel in patients with B-cell malignancies in a routine…
- Trial name
- NCT06785818
- Testing
- Tisagenlecleucel
- Where
- 18 sites in South Korea
- Volunteers
- 500 people
- Sponsor
- Novartis Pharmaceuticals
Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
The Microbiome in Blood Cancer and HLH
The bacteria and viruses in the bowel (gut microbiota; GM) have powerful effects on the immune system. GM changes are seen in patients with auto-immune diseases, where the immune system attacks normal tissues, and cancer, and for…
- Conditions
- Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Haemophagocytic Lymphohistiocytosis
- Trial name
- NCT06734624
- Where
- United Kingdom
- Volunteers
- 750 people
- Sponsor
- University of Nottingham
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma (FL)
Long-term Study to Evaluate Safety and Persistence of GF-CART01
The goal of this observational study is to learn about the long-term safety of GF-CART01 after cell infusion up to 15 years.
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma (FL), Primary Mediastinal Large B-Cell Lymphoma, High Grade B Cell Lymphoma
- Trial name
- NCT06985576
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- GenomeFrontier Therapeutics TW Co., Ltd.
Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies
This will be a multicenter, national, non-interventional, prospective cohort study
- Conditions
- Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Follicular Lymphoma
- Trial name
- NCT05541341
- Testing
- tisagenlecleucel
- Where
- 7 sites in Brazil
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Diffuse Large B Cell Lymphoma, Large B-cell Lymphoma
Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
According to health authorities guidances (FDA 2006, EMA(European Medicines Agency) 2009) for gene therapy clinical trials, observing subjects for delayed adverse events for 15 years is recommended.
- Conditions
- Diffuse Large B Cell Lymphoma, Large B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma Grade 3A
- Trial name
- NCT05377307
- Testing
- Pell's lentiviral-based gene-edited immune cell therapy
- Where
- 5 sites in Taiwan
- Volunteers
- 49 people
- Sponsor
- Pell Bio-Med Technology Co., Ltd.
DLBCL, Glofitamab
Gut Microbiome in DLBCL Treated With Glofitamab
The gut microbiome (GM) has recently emerged as one of the key modifiable factors of response and prognosis to immunotherapy in cancer patients.
- Conditions
- DLBCL, Glofitamab, Gut Biome
- Trial name
- NCT07498920
- Testing
- Gut microbiome analysis
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
B Cell Malignancies, Acute Lymphobkastic Leukemia
A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies
This is a phase I/II trial of SHB-02-CD19, T-cell expressing an anti-CD19 Chimeric-Antigen-Receptor (CAR) in patients with CD19 expressing B-cell malignancies.
- Conditions
- B Cell Malignancies, Acute Lymphobkastic Leukemia, Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)
- Trial name
- NCT07503353
- Testing
- SHB-02-CD19 (anti CD19 CAR-T cells)
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Sheba Medical Center
Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
Long-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.
- Conditions
- Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL, ALL, Adult and Pediatric
- Trial name
- NCT03628612
- Testing
- AUTO CAR T cell therapy
- Where
- 9 sites in United States, Spain and 1 more
- Volunteers
- 500 people
- Sponsor
- Autolus Limited
Lymphoid Malignancies
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with…
- Trial name
- OPAL (NCT04329728)
- Testing
- AVM0703
- Where
- 11 sites in United States
- Volunteers
- 144 people
- Sponsor
- AVM Biotechnology Inc
Hematology, Diffused Large B Cell Lymphoma
A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region
Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy, with over 80,500 estimated new cases diagnosed in the United States in 20231.
- Trial name
- DOMAIN (NCT07065344)
- Where
- 21 sites in Egypt, Iraq and 8 more
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL)
GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors
About this study This is the first study of VTRU200 in people. The main purpose of this study is to find a safe dose of VTRU200 and learn how the medicine behaves in the body.
- Conditions
- Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL), High Risk Myelodysplastic Syndrome, Solid Tumor Malignancies
- Trial name
- NCT07749976
- Testing
- VTRU200
- Volunteers
- 108 people
- Sponsor
- Vitruviae
DLBCL
A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma
LBCL is a cancer of the lymphatic system where B-cells (a type of white blood cell) experience uncontrolled growth. The standard treatment for LBCL is a combination of chemotherapy and immunotherapy, referred to as…
- Trial name
- ALMANAC (NCT07335120)
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
Diffuse Large B-cell Lymphoma
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
The goal of this phase 2 trial is to test the safety and efficacy of zanubrutinib and lenalidomide as maintenance therapy in patients with DLBCL.
- Trial name
- NCT06503263
- Testing
- Zanubrutinib plus Lenalidomide as Maintenance Therapy
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Navy General Hospital, Beijing
Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma
Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)
This Phase I study will evaluate the safety of autologous Epstein-Barr virus-specific T lymphocytes modified to express a constitutively active IL7 receptor (C7R) and a chimeric antigen receptor (CAR) for CD30…
- Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma, ALK-Positive
- Trial name
- ANCILE-30 (NCT07729397)
- Testing
- Autologous C7R.CD30-CAR-EBVSTs
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- The Methodist Hospital Research Institute
Lymphoma, Hodgkin Lymphoma
The Pathogenesis and Prognostic Factors of Lymphoma
The aim of this study is to describe the clinical and genetic characteristics of Chinese lymphoma patients, and to explore the relationship between those characteristics and phatogenesis.
- Conditions
- Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
- Trial name
- NCT06203652
- Testing
- Real-world regimen
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Shanghai Zhongshan Hospital
Diffuse Large B Cell Lymphoma (DLBCL), Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Axatilimab + CAR-T for High-Risk Lymphoma
Axatilimab + CAR-T in High-Risk Lymphoma
- Conditions
- Diffuse Large B Cell Lymphoma (DLBCL), Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma (HGBCL), High-Grade B-Cell Lymphoma, Nos
- Trial name
- NCT07638982
- Testing
- Axatilimab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Northside Hospital, Inc.